Cathie Wood’s ARK Invest Shifts $1.9M into Biotech, Reduces AI Exposure

Cathie Wood's ARK Invest executed significant trades on September 9, 2025, channeling nearly $1.86 million into biotech stocks while trimming positions in an AI-driven health-tech company. The flagship ARK Genomic Revolution ETF (ARKG) acquired 157,000 shares of Prime Medicine (PRME), a gene-editing firm, valued at approximately $620,000. Twist Bioscience (TWST), a synthetic biology company, saw $1.24 million in inflows across ARK's Innovation and Genomic Revolution ETFs.

Prime Medicine's stock has surged 41% year-to-date, contrasting with Twist Bioscience's 46% decline. Meanwhile, ARK reduced its stake in Tempus AI (TEM), signaling a strategic pivot toward biotech innovations. The moves underscore Wood's conviction in genomic disruption, even as market performance diverges sharply among her holdings.